Year All20262025202420232022202120202019 July 16, 2026 Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions July 6, 2026 AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder June 25, 2026 AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets May 28, 2026 AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations May 27, 2026 AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 May 12, 2026 AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update April 27, 2026 AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research April 22, 2026 AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder April 14, 2026 AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences April 8, 2026 AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
July 16, 2026 Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
July 6, 2026 AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
June 25, 2026 AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
May 28, 2026 AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
May 12, 2026 AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
April 27, 2026 AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
April 22, 2026 AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
April 8, 2026 AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
